The NAD+ Quarantine Hypothesis: SASP-Driven NAD+ Depletion as an Active Anti-Inflammatory Strategy Rather Than Passive Metabolic Decline

Current models treat NAD+ decline as a secondary consequence of senescence—we see it differently. We propose that SASP-induced NAD+ depletion through CD38 functions as an evolutionarily conserved "metabolic quarantine," a deliberate withdrawal of resources designed to limit the inflammatory cascade's energy supply.

The conventional view treats NAD+ loss as pathophysiology—basically a failure that drives endothelial dysfunction through eNOS uncoupling and ICAM-1 overexpression. But this framing assumes the decline is unintended. Our hypothesis is that the body systematically depletes NAD+ via CD38 upregulation in macrophages and endothelial cells for a protective purpose: starving senescent cells of the metabolic substrate they need for PARP-mediated DNA repair and sirtuin-driven transcriptional activation, which limits their ability to sustain pro-inflammatory SASP production.

This metabolic quarantine model explains a puzzling observation in the literature—why senescent cells upregulate NAMPT. We think it's a selfish self-preservation strategy: senescent cells locally preserve NAD+ pools to power their own inflammatory phenotype while creating a NAD+-deficient environment that suppresses how neighboring healthy cells respond to inflammatory signals. The endothelial dysfunction we see—eNOS uncoupling, reduced NO production—might therefore be an intentional wound-sealing response rather than passive damage.

The therapeutic implication diverges sharply from the senolytics-first approach. If NAD+ augmentation without senolytic clearance accidentally provides metabolic fuel to SASP-producing cells, it could worsen inflammation—not despite the body's strategic withdrawal of resources, but because of it. Testing this hypothesis means measuring SASP factor production in senescent cells cultured with versus without NAD+ precursors, comparing inflammatory output when CD38 activity is pharmacologically inhibited versus enhanced, and asking whether endothelial dysfunction in aged vasculature reflects active barrier reinforcement rather than passive decline.

If validated, this framework reframes NAD+ decline from "budget cut" to "containment protocol"—the body's strategic retreat to limit damage rather than a failure to maintain function.